Long‐term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy
- 1 January 2002
- journal article
- clinical trial
- Published by Wiley in HIV Medicine
- Vol. 3 (1) , 37-43
- https://doi.org/10.1046/j.1464-2662.2001.00091.x
Abstract
Objective To determine the long‐term antiretroviral efficacy and tolerability of dual protease inhibitor (PI) therapy with indinavir (IDV)/ritonavir (RTV) at 400/400 mg twice a day (BID) in combinati...Keywords
This publication has 15 references indexed in Scilit:
- A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and EfficacyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- The Danish Protease Inhibitor Study: A Randomized Study Comparing the Virological Efficacy of 3 Protease Inhibitor–Containing Regimens for the Treatment of Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 2000
- Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavirAIDS, 2000
- Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individualsAIDS, 2000
- Dual Protease Inhibitor Therapy in HIV-Infected Patients: Pharmacologic Rationale and Clinical BenefitsAnnual Review of Pharmacology and Toxicology, 2000
- Alterations in Serum Levels of Lipids and Lipoproteins with Indinavir Therapy for Human Immunodeficiency Virus‐Infected PatientsClinical Infectious Diseases, 1999
- Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trialAIDS, 1999
- Changes in renal function associated with indinavirAIDS, 1998
- Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients?AIDS, 1998
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998